Abivax (LTS:0RA9) Days Sales Outstanding : 0.00 (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Abivax Days Sales Outstanding?

Abivax's average Accounts Receivable for the six months ended in Dec. 2024 was €0.00 Mil. Abivax's Revenue for the six months ended in Dec. 2024 was €0.00 Mil.

The historical rank and industry rank for Abivax's Days Sales Outstanding or its related term are showing as below:

During the past 12 years, Abivax's highest Days Sales Outstanding was 175309.50. The lowest was 12519.21. And the median was 93914.36.

LTS:0RA9's Days Sales Outstanding is not ranked ^*
in the Biotechnology industry.
Industry Median: 69.63
* Ranked among companies with meaningful Days Sales Outstanding only.

Abivax's Days Sales Outstanding stayed the same from Jun. 2023 (0.00) to Dec. 2024 (0.00).

Abivax Days Sales Outstanding Historical Data

The historical data trend for Abivax's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abivax Days Sales Outstanding Chart

Abivax Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Days Sales Outstanding

Get a 7-Day Free Trial

Abivax Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Dec24
Days Sales Outstanding	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Abivax's Days Sales Outstanding

For the Biotechnology subindustry, Abivax's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abivax's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abivax's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Abivax's Days Sales Outstanding falls into.

Save Embed

;

Save Embed

;

Abivax Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Abivax's Days Sales Outstanding for the fiscal year that ended in Dec. 2024 is calculated as

	Days Sales Outstanding (A: Dec. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Dec. 2024 ))	/	count )	/	Revenue (A: Dec. 2024 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365
=	0					/	0	*	365
=	N/A

Abivax's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding (Q: Dec. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Dec. 2024 ))	/	count )	/	Revenue (A: Dec. 2024 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365 / 2
=	0					/	0	*	365 / 2
=	N/A

Abivax (LTS:0RA9) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Abivax Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Abivax's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Abivax Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (LTS:0RA9) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

ABVX:USA AAVXF:USA ABVX:France 2X1:Germany

Address

7-11 boulevard Haussmann, Paris, FRA, 75009

Website

https://www.abivax.com

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Abivax Headlines

No Headlines